Periphagen Holdings develops a gene therapy platform based on a Herpes Simplex Virus. The company is positioning itself to expand as a clinical‑stage biopharmaceutical company to develop new treatments for patients with significant unmet medical need. Periphagen was formed after buying the former Diamyd, Inc. in October 2012, acquiring the related gene therapy rights. The company has secured a financing commitment from a life science fund that can provide up to USD 16 million, of which USD 6.5 million has been closed. That financing is intended to supply both capital and expertise to advance Periphagen’s development efforts. Diamyd Medical is a shareholder and retains other financial interests tied to Periphagen’s technology, including milestone and royalty potential.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2014